Search clinical trials for: oral JAK inhibitor

Total 97925 results

Canadian Network for Observational Drug Effect...
Canadian Institutes of Health Research (CIHR); Drug Safety and Effectiveness...

Completed

Incretin-based Drugs and Acute Pancreatitis

Diabetes Mellitus, Type 2

Canada
Acorda Therapeutics

Completed

A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets

Parkinson Disease

United States
Biogen

Completed

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

Healthy

United States
National Health Research Institutes, Taiwan

Completed

An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer

Hormone-refractory Prostate Cancer

Taiwan
Sanofi

Terminated

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation (BOREALIS-AF)

Atrial Fibrillation

South Africa, Thailand, Chile, Guatemala, Ukraine, United States, Argentina, Australia, Austria, Belarus, Brazil, Bulgaria, Canada, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Egypt, Estonia, Finland, France, Greece, India, ... and more
University of Washington
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Familial Atherosclerosis Treatment Study (FATS)

Myocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Coronary Disease | Coronary Arteriosclerosis
Vertex Pharmaceuticals Incorporated

Completed

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Rheumatoid Arthritis

United States, Argentina, Bulgaria, Czech Republic, Estonia, Germany, Hungary, Mexico, Poland, Romania, Russian Federation, Serbia, Slovakia, Ukraine
AstraZeneca
Bristol-Myers Squibb

Completed

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

Type 2 Diabetes

United States, Canada, Mexico, Russian Federation
University of Southern California
Society of Family Planning

Completed

The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone Contraception (NET)

Pregnancy | HIV | AIDS

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)

Sarcoma | Cancer
University of Bergen

Unknown

Treatment of Acute Leukemia Relapse After Allotransplantation

Acute Myeloid Leukemia

Norway
University of Michigan
National Institute of Dental and Craniofacial Research (NIDCR)

Completed

Oral Health in Breast Cancer Survivors on Aromatase Inhibitors

Quality of Life | Periodontal Disease

United States
Vertex Pharmaceuticals Incorporated

Completed

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Rheumatoid Arthritis

United States, Denmark, Estonia, Lithuania, Netherlands, South Africa
Bayer

Completed

Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis

Chronic Bronchitis

Spain, China, Argentina, Germany, Greece, Portugal, Canada, Netherlands, Australia, Peru, Philippines, Belgium, Switzerland, Chile, Italy, Thailand, Mexico, Lithuania, South Africa, Croatia, France, Colombia, Indonesia, Latvia, Hong Kong, United Kingdom and more
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

Venous Thromboembolism

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Korea, Republic of, New Zealand, Poland, India, United States, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Switzerland, Taiwan, Brazil, Denmark, German... and more
UCB Pharma

Completed

Prostaglandin E1 in Outpatients With Intermittent Claudication

Stage II Peripheral Arterial Occlusive Disease | Intermittent Claudication Fontaine Stage II PAOD

Germany
Massachusetts General Hospital
National Institute of Mental Health (NIMH)

Completed

Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression

Depression

United States
Pfizer

Completed

A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

United States, Canada, Poland, Serbia, Germany, Ukraine, Taiwan, Mexico, Colombia, Hungary, Puerto Rico
Bayer

Completed

A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease

Pelvic Inflammatory Disease

China, Philippines, Thailand, Pakistan, Taiwan, Indonesia, Korea, Republic of
Boehringer Ingelheim

Completed

Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers

Healthy
National Cancer Institute (NCI)

Completed

Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer

Radiation Toxicity | Malignant Neoplasm | Adult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Ependymoma | Adult Mixed Glioma | Adult Oligodendroglioma | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the... and other conditions

United States
The Medicines Company

Terminated

A Clinical Trial to Demonstrate the Efficacy of Cangrelor (PCI)

Myocardial Infarction (MI) | Acute Coronary Syndromes (ACS)

United States
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

Pulmonary Embolism

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Switzerland, United States, New Zealand, Poland, India, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Estonia, Thailand, Brazil, Germany, Korea, Republic... and more
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study

Venous Thrombosis

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Korea, Republic of, United States, New Zealand, Poland, India, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Switzerland, Brazil, Denmark, Germany, Norw... and more
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Radiation Toxicity | Oral Complications | Drug/Agent Toxicity by Tissue/Organ

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer

Lymphoma | Leukemia | Oral Complications

United States
University of Washington
National Cancer Institute (NCI)

Completed

Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Stage III Squamous Cell Carcinoma of the Hypopharynx | Stage III Squamous Cell Carcinoma of the Larynx | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Nasopharynx | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IV Squamous... and other conditions

United States
Pfizer

Completed

Co-Administration Of Methotrexate And CP-690,550

Rheumatoid Arthritis

United States
Pfizer

Completed

Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks

Rheumatoid Arthritis

United States, Germany, Italy, Spain, Canada, Belgium, Slovakia, Brazil, Mexico
Pfizer

Completed

A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Costa Rica, Czech Republic, Germany, Croatia, Canada, Korea, Republic of, Spain, Bosnia and Herzegovina, Australia, Bulgaria, Mexico, Slovakia, Poland, Philippines, Chile, Denmark, Dominican Republic, Finland, T... and more
Duke University
Pfizer; Agency for Healthcare Research and Quality (AHRQ)

Completed

Study of an Intervention to Improve Use of Life-saving Medications for Heart Disease (PILOT-EBM)

Cardiovascular Disease

United States
National Taiwan University Hospital

Unknown

Oral Versus IV Proton Pump Inhibitor in High-risk Bleeding Peptic Ulcers After Endoscopic Hemostasis

Peptic Ulcers

Taiwan
S*BIO

Completed

A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis

Myeloproliferative Disorders | Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis

United States, Australia
Kirby Institute
National Heart, Lung, and Blood Institute (NHLBI); St Vincent's Hospital, Sydney

Completed

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

Cardiovascular Disease | HIV-Associated Lipodystrophy Syndrome

Australia
Janssen-Ortho Inc., Canada

Completed

CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults

Attention Deficit Disorder With Hyperactivity
Federal University of São Paulo

Unknown

Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea

Quality of Life | Seborrheic Dermatitis | Seborrhea

Brazil
Swedish Medical Center
Pfizer

Completed

Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma

Adenocarcinoma | Lung Cancer

United States
Pfizer

Completed

A Study Of The Taste Of Different Oral Liquid Preparations Of CP-690,550 In Trained Adult Product Testers

Arthritis, Rheumatoid

United States
Pfizer

Completed

A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems

HIV Infections | Candidiasis, Esophageal

United States, Canada
Universitas Diponegoro

Recruiting

Combination Oral Acetazolamide and Intravenous Furosemide on Acute Decompensated Heart Failure Outcomes (COAF-HF)

Acute Decompensated Heart Failure

Indonesia
Chang Gung Memorial Hospital

Recruiting

Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN

Stevens-Johnson Syndrome | Toxic Epidermal Necrolysis

Taiwan
Institut Cancerologie de l'Ouest

Not yet recruiting

Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases (BRADI)

Brain Metastases | Radionecrosis of Brain

France
Yuanquan Yang

Not yet recruiting

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Advanced Malignant Solid Neoplasm | Hematopoietic and Lymphatic System Neoplasm

United States
The University of Hong Kong

Not yet recruiting

Acupressure on Xerostomia in Head and Neck Cancer Patients

Head and Neck Cancer | Xerostomia

Hong Kong
University Hospital, Clermont-Ferrand

Not yet recruiting

Validation of a French Version of the DHEQ (DHEQ-VALID)

Quality of Life | Dentin Hypersensitivity

France
Biocodex
Exystat

Not yet recruiting

Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3 (CRYSTAL)

Primary Hyperoxaluria Type 3 | Primary Hyperoxaluria Type 2 | Primary Hyperoxaluria Type 1
AbbVie

Not yet recruiting

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up)

Atopic Dermatitis
Chengdu Baiyu Pharmaceutical Co., Ltd.

Recruiting

A Phase l Study of By101298, an Oral DNA-PK Inhibitor, in Patients With Advanced Solid Tumors

Solid Tumor, Adult

China
Zai Lab (Hong Kong), Ltd.

Recruiting

A Study to Compare the Effect of Omadacycline Versus Moxifloxacin in Healthy Adult Volunteers

Healthy Volunteer

China
Wei XIA, PhD

Recruiting

Effect of Health Diary on Self-management in Adolescent Patients With Orthodontic Fixed Appliance: A Randomized Controlled Trial

Oral Hygiene | Self-Management

China

Search clinical trials for: oral JAK inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations